Paracrine Activation of Hepatic CB1 Receptors by??Stellate Cell-Derived Endocannabinoids Mediates??Alcoholic Fatty Liver, Cell Metabolism, vol.7, issue.3, pp.227-262, 2008. ,
DOI : 10.1016/j.cmet.2007.12.007
Antifibrogenic role of the cannabinoid receptor CB2 in the liver, Gastroenterology, vol.128, issue.3, pp.742-55, 2005. ,
DOI : 10.1053/j.gastro.2004.12.050
Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity ,
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice, Journal of Clinical Investigation, vol.118, issue.9, pp.3160-3169, 2008. ,
DOI : 10.1172/JCI34827
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis, Nature Medicine, vol.30, issue.6, pp.671-677, 2006. ,
DOI : 10.1038/nm1421
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice, Journal of Clinical Investigation, vol.118, issue.3, pp.829-867, 2008. ,
DOI : 10.1172/JCI34275
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, vol.330, issue.1 ,
DOI : 10.1002/hep.21641
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice, American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, vol.284, issue.2, pp.345-53, 2003. ,
DOI : 10.1152/ajpregu.00545.2002
The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells, Molecular Pharmacology, vol.63, issue.4, pp.908-922, 2003. ,
DOI : 10.1124/mol.63.4.908
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, Journal of Clinical Investigation, vol.112, issue.1, pp.91-100, 2003. ,
DOI : 10.1172/JCI200317797
Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C, Gastroenterology, vol.134, issue.2, pp.432-441, 2008. ,
DOI : 10.1053/j.gastro.2007.11.039
HEPATIC FIBROSIS: Molecular Mechanisms and Drug Targets, Annual Review of Pharmacology and Toxicology, vol.45, issue.1, pp.605-633, 2005. ,
DOI : 10.1146/annurev.pharmtox.45.120403.095906
68 Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C, Journal of Hepatology, vol.40, pp.63-71, 2005. ,
DOI : 10.1016/S0168-8278(04)90068-2
Influence of Cannabis Use on Severity of Hepatitis C Disease, Clinical Gastroenterology and Hepatology, vol.6, issue.1, pp.69-75, 2008. ,
DOI : 10.1016/j.cgh.2007.10.021
Obesity, Inflammation, and Insulin Resistance, Gastroenterology, vol.132, issue.6, pp.2169-80, 2007. ,
DOI : 10.1053/j.gastro.2007.03.059
Inflammation and metabolic disorders, Nature, vol.314, issue.7121, pp.860-867, 2006. ,
DOI : 10.1038/nature05485
MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity, Journal of Clinical Investigation, vol.116, issue.6, pp.1494-505, 2006. ,
DOI : 10.1172/JCI26498DS1
Cannabinoid-based drugs as anti-inflammatory therapeutics, Nature Reviews Immunology, vol.267, issue.5, pp.400-411, 2005. ,
DOI : 10.1002/glia.10177
CB2 receptor antagonism reduces diet-induced obesity, insulin resistance and hepatic steatosis, Hepatology, vol.46, p.308, 2007. ,